Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma
- PMID: 37290997
- DOI: 10.1016/j.clml.2023.05.005
Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma
Abstract
Multiple myeloma (MM) represents ∼1% of all cancers and is the second most common hematologic malignancy worldwide. The incidence of MM is at least two times higher in Blacks/African Americans compared with their White counterparts, and Hispanics/Latinxs are among the youngest patients diagnosed with the disease. Recent advances in available treatments for MM have demonstrated significant improvement in survival outcomes; however, patients from non-White racial/ethnic groups clinically benefit less due to multiple factors including access to care, socioeconomic status, medical mistrust, underutilization of novel therapies, and exclusion from clinical trials. Health inequities in disease characteristics and risk factors based on race also contribute to inequities in outcomes. In this review, we highlight racial/ethnic factors as well as structural barriers attributed to variations in MM epidemiology and management. We focus on three populations-Black/African American, Hispanic/Latinx, and American Indian/Alaska Native-and review factors that healthcare professionals may consider when treating patients of color. We offer tangible advice for healthcare professionals on how to incorporate cultural humility into their practice by following the five key steps: establishing trust, respecting cultural diversity, undergoing cross-cultural training, counseling patients on appropriate available clinical trial options, and connecting patients to community resources. The outlined recommendations will help the medical community to better understand and apply the important concept of cultural humility into their practice to provide the best care for all their patients, regardless of race/ethnicity.
Keywords: Cultural humility; Diverse racial/ethnic group; Ethnicity; Inequity; Race.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure BB: Consulting – Janssen, Oncopeptides, Sanofi; Honoraria – WebMD; AP: Consulting – Bristol Myers Squibb; Employment at Flatiron Health Inc., an independent subsidiary of Roche, and stock ownership in Roche; JM: Consulting – Amgen, Karyopharm Therapeutics, Sanofi, Janssen, Bristol Myers Squibb, GlaxoSmithKline, Takeda; Data Safety Monitoring Board – Sanofi.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
